ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases americanpharmaceuticalreview
April 07, 2021?n-Lorem Foundation announced a new partnership with Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases. -
Novartis Buys Rare Drug Voucher for $130M From Ultragenyx
biospace
December 20, 2017Novartis?picked up a priority review voucher in a?$130 million deal?with California-based?Ultragenyx Pharmaceutical Inc.The PRV is for rare pediatric diseases. -
M&As this week: Catalent, Ultragenyx Pharmaceutical
pharmaceufical-technology
September 25, 2017The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors. -
Phase 3 fail prompts Ultragenyx to can muscle disease drug
fiercebiotech
August 24, 2017A phase 3 fail wiped more than 10% off Ultragenyx's share price. -
Ultragenyx stumbles in P3 trial for severe muscle disease
pharmafile
August 23, 2017Ultragenyx has revealed results from a Phase 3 trial into the treatment of GNE myopathy showed that its compound did not successfully meet the primary or secondary endpoints of the study.
Pharma Sources Insight January 2025
